Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 14, 2009

ImmuneRegen Taps University of Pittsburgh Scientist to Work on Preclinical Flu Vaccine

  • ImmuneRegen BioSciences entered a sponsored research agreement with Ted M. Ross, Ph.D., an assistant professor at the University of Pittsburgh's Center for Vaccine Research. Dr. Ross will explore the use of the company’s lead influenza product, Viprovex, which is at the preclinical stage, as an adjuvant to novel influenza vaccines.

    ImmuneRegen is already developing the compound for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. Viprovex is a derivative of Homspera, which is in advanced preclinical testing as a stem cell stimulant to help wound healing.

    Previous studies performed at other research facilities revealed Viprovex used as a vaccine adjuvant increased concentrations in blood of antibodies against both the virus used for vaccination as well as cross-reactive antibodies against different influenza strains, according to the company.



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »